The American Journal of Medicine
Volume 120, Issue 3, Supplement 1 , Pages S26-S34 , March 2007

Therapeutic Options for Modifying Cardiometabolic Risk Factors

  • Louis J. Aronne, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Louis J. Aronne, MD, Comprehensive Weight Control Program, New York–Presbyterian Hospital, 1165 York Avenue, New York, New York 10021.

References 

  1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–1555
  2. Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine. 2006;29:109–118
  3. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–976
  4. NHLBI Obesity Education Initiative Working Group. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute/North American Association for the Study of Obesity (NIH/NHLBI/NAASO); 2000;October. NIH Publication No. 00-4084
  5. Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591–602
  6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  7. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403
  8. Orchard TJ, Temprosa M, Goldberg R, et al. Diabetes Prevention Program Research Group The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program Randomized Trial. Ann Intern Med. 2005;142:611–619
  9. Ryan DH, Kaiser P, Bray GA. Sibutramine: a novel new agent for obesity treatment. Obes Res. 1995;3(suppl 4):553S–559S
  10. Buckett WR, Thomas PG, Luscombe GP. The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:575–584
  11. Astrup A, Toubro S. When, for whom and how to use sibutramine?. Int J Obes Relat Metab Disord. 2001;25(suppl 4):S2–S7
  12. James WP, Astrup A, Finer N, et al. STORM [Sibutramine Trial of Obesity Reduction and Maintenance] Study Group Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet. 2000;356:2119–2125
  13. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353:2111–2120
  14. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235–242
  15. Sjostrom L, Rissanen A, Andersen T, et al. European Multicentre Orlistat Study Group Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–172
  16. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–167
  17. Kay JP, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457–1461
  18. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100
  19. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004;12:661–668
  20. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience for the RIO-Europe study. Lancet. 2005;365:1389–1397
  21. Williams CM, Kirkham TC. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology. 1999;143:315–317
  22. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol. 2002;136:550–557
  23. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843
  24. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J RIO–North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO–North America: a randomized controlled trial. JAMA. 2006;295:761–775
  25. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet. 2006;368:1660–1672
  26. Despres JP, Golay A, Sjostrom L Rimonabant in Obesity–Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–2134

PII: S0002-9343(07)00035-6

doi: 10.1016/j.amjmed.2007.01.005

The American Journal of Medicine
Volume 120, Issue 3, Supplement 1 , Pages S26-S34 , March 2007

Article Tools

* Image Usage & Resolution